Kyverna Therapeutics (KYTX) to Release Earnings on Monday

Key Points

• Kyverna Therapeutics is set to release its Q2 2025 earnings report on August 11, with analysts predicting a loss of ($1.00) per share.
• The company's stock recently opened at $3.41 and has a market capitalization of $147.55 million, with a significant trading beta of 3.04.
• HC Wainwright has upgraded Kyverna Therapeutics to a buy rating with a price target increase from $4.00 to $5.00, reflecting positive sentiment from multiple analysts.

Kyverna Therapeutics (NASDAQ:KYTX - Get Free Report) is expected to be announcing its Q2 2025 earnings results before the market opens on Monday, August 11th. Analysts expect the company to announce earnings of ($1.00) per share for the quarter.

Kyverna Therapeutics (NASDAQ:KYTX - Get Free Report) last announced its earnings results on Tuesday, May 13th. The company reported ($1.03) earnings per share for the quarter, beating the consensus estimate of ($1.21) by $0.18. On average, analysts expect Kyverna Therapeutics to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Kyverna Therapeutics Stock Performance

KYTX traded down $0.07 during trading on Friday, hitting $3.24. The stock had a trading volume of 176,559 shares, compared to its average volume of 371,648. The firm has a market capitalization of $140.03 million, a P/E ratio of -0.96 and a beta of 3.05. Kyverna Therapeutics has a twelve month low of $1.78 and a twelve month high of $8.78. The company's 50-day moving average price is $3.39 and its 200 day moving average price is $2.80.

Analyst Ratings Changes

Separately, HC Wainwright upgraded Kyverna Therapeutics from a "neutral" rating to a "buy" rating and boosted their target price for the stock from $4.00 to $5.00 in a research report on Tuesday, May 27th. Five investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $15.60.

Institutional Investors Weigh In On Kyverna Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Rhumbline Advisers lifted its holdings in shares of Kyverna Therapeutics by 22.0% in the first quarter. Rhumbline Advisers now owns 31,614 shares of the company's stock valued at $61,000 after purchasing an additional 5,694 shares in the last quarter. AQR Capital Management LLC acquired a new position in shares of Kyverna Therapeutics during the 1st quarter worth approximately $137,000. Cubist Systematic Strategies LLC lifted its stake in Kyverna Therapeutics by 31.1% in the 1st quarter. Cubist Systematic Strategies LLC now owns 68,628 shares of the company's stock valued at $132,000 after buying an additional 16,267 shares in the last quarter. Finally, Bank of America Corp DE grew its holdings in Kyverna Therapeutics by 41.6% during the 4th quarter. Bank of America Corp DE now owns 21,788 shares of the company's stock valued at $81,000 after buying an additional 6,400 shares during the last quarter. 18.08% of the stock is currently owned by institutional investors and hedge funds.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.